Evaluation of the safety profile of COVID-19 vaccines: a rapid review
Q Wu, MZ Dudley, X Chen, X Bai, K Dong, T Zhuang… - BMC medicine, 2021 - Springer
Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …
Administration of COVID-19 vaccines in immunocompromised patients
Since the beginning of vaccination programs against COVID-19 in different countries,
several populations such as patients with specific immunological conditions have been …
several populations such as patients with specific immunological conditions have been …
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in …
MD Tanriover, HL Doğanay, M Akova, HR Güner… - The Lancet, 2021 - thelancet.com
Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown
to be well tolerated with a good safety profile in individuals aged 18 years and older in …
to be well tolerated with a good safety profile in individuals aged 18 years and older in …
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
Objective To estimate the effectiveness of the inactivated whole virus vaccine, CoronaVac
(Sinovac Biotech), against symptomatic covid-19 in the elderly population of São Paulo …
(Sinovac Biotech), against symptomatic covid-19 in the elderly population of São Paulo …
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised …
B Han, Y Song, C Li, W Yang, Q Ma, Z Jiang… - The Lancet Infectious …, 2021 - thelancet.com
Background A vaccine against SARS-CoV-2 for children and adolescents will play an
important role in curbing the COVID-19 pandemic. Here we aimed to assess the safety …
important role in curbing the COVID-19 pandemic. Here we aimed to assess the safety …
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
AC Medeiros-Ribeiro, NE Aikawa, CGS Saad… - Nature medicine, 2021 - nature.com
CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in
several countries. However, its immunogenicity in immunocompromised individuals has not …
several countries. However, its immunogenicity in immunocompromised individuals has not …
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong
CKP Mok, CA Cohen, SMS Cheng, C Chen… - …, 2022 - Wiley Online Library
Background and objective Few head‐to‐head evaluations of immune responses to different
vaccines have been reported. Methods Surrogate virus neutralization test (sVNT) antibody …
vaccines have been reported. Methods Surrogate virus neutralization test (sVNT) antibody …
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control …
MDT Hitchings, OT Ranzani, MSS Torres… - The Lancet Regional …, 2021 - thelancet.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant,
Gamma, emerged in the city of Manaus in late 2020 during a large resurgence of …
Gamma, emerged in the city of Manaus in late 2020 during a large resurgence of …
Neutralisation of SARS-CoV-2 lineage P. 1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an …
Background Mutations accrued by SARS-CoV-2 lineage P. 1—first detected in Brazil in early
January, 2021—include amino acid changes in the receptor-binding domain of the viral …
January, 2021—include amino acid changes in the receptor-binding domain of the viral …
The mucosal and serological immune responses to the novel coronavirus (SARS-CoV-2) vaccines
RWY Chan, S Liu, JY Cheung, JGS Tsun… - Frontiers in …, 2021 - frontiersin.org
Background Although the serological antibody responses induced by SARS-CoV-2 vaccines
are well characterized, little is known about their ability to elicit mucosal immunity. Objectives …
are well characterized, little is known about their ability to elicit mucosal immunity. Objectives …